Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Improves Accuracy of Skin Cancer Detection

By LabMedica International staff writers
Posted on 14 Nov 2025

Diagnosing melanoma accurately in people with darker skin remains a longstanding challenge. More...

Many existing artificial intelligence (AI) tools detect skin cancer more reliably in lighter skin tones, often missing early signs in patients with darker skin. This contributes to later-stage diagnoses and poorer outcomes. To address this diagnostic gap, researchers have developed a new AI-based method that improves skin tone recognition and enhances melanoma detection across diverse patient groups.

The collaborative research led by Fox Chase Cancer Center (Philadelphia, PA, USA) introduces a more equitable approach to training AI tools for dermatology. The researchers focused on understanding why existing AI systems underperform in darker skin tones. They found that most models are trained on narrow datasets—often sourced from limited geographic regions, hospitals, or time periods—and fail to represent the full spectrum of human skin color.

This lack of diversity leads to biased diagnostic results that favor lighter-skinned individuals. Recent imaging and AI studies have sought to enhance detection across skin types, but few have directly examined how skin color affects diagnostic performance. To overcome this limitation, the team developed MST-AI, a method based on the Monk Skin Tone (MST) scale, which uses 10 distinct shades to capture a wider range of skin tones. MST-AI estimates skin color more precisely and was tested on a large public dataset of skin cancer images.

The approach, highlighted in the Journal of Imaging, provides stronger accuracy and more reliable skin tone assignments compared with existing techniques, creating a more representative foundation for AI training. The MST-AI method helps correct skin tone imbalances in dermatology datasets, allowing AI models to learn from a more inclusive sample. This can improve early detection, reduce missed or delayed melanoma diagnoses in people of color, and support the development of fairer clinical AI tools.

“Our results show that MST-AI gives more accurate and reliable skin tone estimates than the other methods, based on trusted evaluation scores. It helps correct skin tone imbalances in large dermatology datasets, creating a better base for accurate and fair diagnosis,” said Hayan Lee, PhD, corresponding author on the study.

Related Links:
Fox Chase Cancer Center


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.